Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Nature Genetics

• Publication date

  2018-04-16

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/s41588-018-0086-zPMID 29662167PMCID PMC6372064
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• DESNT: A Poor Prognosis Category of Human Prostate Cancer.

  2017cited by this paper
• Mutational signature analysis identifies MUTYH deficiency in colorectal cancers and adrenocortical carcinomas

  2017cited by this paper
• Mutations in the NOT Genes or in the Translation Machinery Similarly Display Increased Resistance to Histidine Starvation

  2017cited by this paper
• Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

  2016cited by this paper
• Landscape of somatic mutations in 560 breast cancer whole genome sequences

  2016cited by this paper
• Prostate cancer

  2016cited by this paper
• Decipher Genomic Classifier Measured on Prostate Biopsy Predicts Metastasis Risk.

  2016cited by this paper
• Adaptive Estimation with Partially Overlapping Models.

  2016cited by this paper
• Overexpression and knock-down studies highlight that a disintegrin and metalloproteinase 28 controls proliferation and migration in human prostate cancer

  2016cited by this paper
• Genomic Predictors of Outcome in Prostate Cancer.

  2015cited by this paper
• Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.

  2015cited by this paper
• Concurrent deletion of 16q23 and PTEN is an independent prognostic feature in prostate cancer

  2015cited by this paper
• Upregulation of miR-556-5p promoted prostate cancer cell proliferation by suppressing PPP2R2A expression.

  2015cited by this paper
• Coordinate loss of MAP3K7 and CHD1 promotes aggressive prostate cancer.

  2015cited by this paper
• Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer.

  2015cited by this paper
• Analysis of the Genetic Phylogeny of Multifocal Prostate Cancer Identifies Multiple Independent Clonal Expansions in Neoplastic and Morphologically Normal Prostate Tissue

  2015cited by this paper
• Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial.

  2015cited by this paper
• Integrative clinical genomics of advanced prostate cancer.

  2015cited by this paper
• Distinctive Behaviors of Druggable Proteins in Cellular Networks

  2015cited by this paper
• Targeting the MLL complex in castration resistant prostate cancer

  2015cited by this paper
• Putative Breast Cancer Driver Mutations in TBX3 Cause Impaired Transcriptional Repression

  2015cited by this paper
• canSAR: an updated cancer research and drug discovery knowledgebase

  2015cited by this paper
• Spatial genomic heterogeneity within localized, multifocal prostate cancer

  2015cited by this paper
• DNA-PKcs-Mediated Transcriptional Regulation Drives Prostate Cancer Progression and Metastasis.

  2015cited by this paper
• Castration radiosensitizes prostate cancer tissue by impairing DNA double-strand break repair

  2015cited by this paper
• The Molecular Taxonomy of Primary Prostate Cancer.

  2015cited by this paper
• Current perspectives on FOXA1 regulation of androgen receptor signaling and prostate cancer

  2015cited by this paper
• DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.

  2015cited by this paper
• The Evolutionary History of Lethal Metastatic Prostate Cancer

  2015cited by this paper
• Clinical significance of different types of p53 gene alteration in surgically treated prostate cancer

  2014cited by this paper
• COSMIC: exploring the world's knowledge of somatic mutations in human cancer

  2014cited by this paper
• The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer

  2014cited by this paper
• Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study.

  2014cited by this paper
• Heterogeneity of genomic evolution and mutational profiles in multiple myeloma

  2014cited by this paper
• Frequent germline deleterious mutations in DNA repair genes in familial prostate cancer cases are associated with advanced disease

  2014cited by this paper
• Integrative analysis of FOXP1 function reveals a tumor-suppressive effect in prostate cancer.

  2014cited by this paper
• Recurrent copy number alterations in prostate cancer: an in silico meta-analysis of publicly available genomic data.

  2014cited by this paper
• TBLR1 as an androgen receptor (AR) coactivator selectively activates AR target genes to inhibit prostate cancer growth.

  2014cited by this paper
• ROBO1, a tumor suppressor and critical molecular barrier for localized tumor cells to acquire invasive phenotype: Study in African‐American and Caucasian prostate cancer models

  2014cited by this paper
• Punctuated evolution of prostate cancer genomes.

  2013cited by this paper
• CHD1 is a 5q21 tumor suppressor required for ERG rearrangement in prostate cancer.

  2013cited by this paper
• REST mediates androgen receptor actions on gene repression and predicts early recurrence of prostate cancer

  2013cited by this paper
• Drugging cancer genomes

  2013cited by this paper
• Deciphering Signatures of Mutational Processes Operative in Human Cancer

  2013cited by this paper
• Recurrent deletion of 3p13 targets multiple tumour suppressor genes and defines a distinct subgroup of aggressive ERG fusion‐positive prostate cancers

  2013cited by this paper
• Signatures of mutational processes in human cancer

  2013cited by this paper
• Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer.

  2013cited by this paper
• Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer.

  2013cited by this paper
• canSAR: updated cancer research and drug discovery knowledgebase

  2013cited by this paper
• Androgen receptor signaling regulates DNA repair in prostate cancers.

  2013cited by this paper
• Somatic Alterations Contributing to Metastasis of a Castration‐Resistant Prostate Cancer

  2013cited by this paper
• Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer

  2012cited by this paper
• The Life History of 21 Breast Cancers

  2012cited by this paper
• Objective assessment of cancer genes for drug discovery

  2012cited by this paper
• Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells

  2012cited by this paper
• Bradley-Terry Models in R: The BradleyTerry2 Package

  2012cited by this paper
• Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemia

  2012cited by this paper
• Identification of novel CHD1-associated collaborative alterations of genomic structure and functional assessment of CHD1 in prostate cancer

  2012cited by this paper
• Copynumber: Efficient algorithms for single- and multi-track copy number segmentation

  2012cited by this paper
• The Mutational Landscape of Lethal Castrate Resistant Prostate Cancer

  2012cited by this paper
• Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes

  2012cited by this paper
• Protein interaction data curation: the International Molecular Exchange (IMEx) consortium

  2012cited by this paper
• Regulation of the MDM2-P53 pathway and tumor growth by PICT1 via nucleolar RPL11

  2011cited by this paper
• Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study.

  2011cited by this paper
• CASZ1, a candidate tumor-suppressor gene, suppresses neuroblastoma tumor growth through reprogramming gene expression

  2011cited by this paper
• Somatic Mutations in the Chromatin Remodeling Gene ARID1A Occur in Several Tumor Types

  2011cited by this paper
• FOXO1 inhibits Runx2 transcriptional activity and prostate cancer cell migration and invasion.

  2011cited by this paper
• Integrative genomic profiling of human prostate cancer.

  2010cited by this paper
• Fast and accurate long-read alignment with Burrows–Wheeler transform

  2010cited by this paper
• Distinct genomic alterations in prostate cancers in Chinese and Western populations suggest alternative pathways of prostate carcinogenesis.

  2010cited by this paper
• The genomic complexity of primary human prostate cancer

  2010cited by this paper
• Characterisation of prostate cancer lesions in heterozygous Men1 mutant mice

  2010cited by this paper
• Allele-specific copy number analysis of tumors

  2010cited by this paper
• Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate

  2009cited by this paper
• Identification of a prostate cancer susceptibility gene on chromosome 5p13q12 associated with risk of both familial and sporadic disease

  2009cited by this paper
• Copy Number Analysis Indicates Monoclonal Origin of Lethal Metastatic Prostate Cancer

  2009cited by this paper
• Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis

  2009cited by this paper
• Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads

  2009cited by this paper
• SUMO-specific protease 1 (SENP1) reverses the hormone-augmented SUMOylation of androgen receptor and modulates gene responses in prostate cancer cells.

  2009cited by this paper
• Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor.

  2008cited by this paper
• SUMOrganization of the nucleus.

  2007cited by this paper
• Common fragile sites, extremely large genes, neural development and cancer.

  2006cited by this paper
• Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis

  2005cited by this paper
• BIOINFORMATICS ORIGINAL PAPER

  year unknowncited by this paper

• Pan-cancer bone metastasis atlas at single-cell resolution identifies a distinct tumor-associated macrophage subset for mediating Denosumab-induced immunosensitization in lung cancer bone metastasis

  2026cites this paper
• Systems biology successes and areas for opportunity in prostate cancer

  2025cites this paper
• Repurposing Mercaptopurine Through Collateral Lethality to Treat Cancers with Somatic RB1–NUDT15 Loss

  2025cites this paper
• Somatic evolution of prostate cancer: mutation, selection, and epistasis across disease stages

  2025cites this paper
• Pathogenic variants reveal candidate genes for prostate cancer germline testing for men of African ancestry

  2025cites this paper
• Letter to the Editor (Correspondence): Re: Prognostic Value of PARP1 and PARP2 Copy Number Alterations in Prostate Cancer.

  2025cites this paper
• Genomic and transcriptomic sequencing in prostate cancer

  2025cites this paper
• Cyclic nucleotide phosphodiesterases as drug targets.

  2025cites this paper
• The Germline and Somatic Origins of Prostate Cancer Heterogeneity

  2025cites this paper
• The landscape of N6-methyladenosine in localized primary prostate cancer

  2025cites this paper
• Molecular subtypes of metastatic prostate cancer: from pathophysiology to diagnosis

  2025cites this paper
• Prostate cancer stem cell dynamics in the evolution of drug resistance.

  2025cites this paper
• Exploring the tumor genomic landscape of aggressive prostate cancer by whole‐genome sequencing of tissue or liquid biopsies

  2024influential citation
• Genomic evolution shapes prostate cancer disease type

  2024cites this paper
• scSemiProfiler: Advancing large-scale single-cell studies through semi-profiling with deep generative models and active learning

  2024cites this paper
• Pan-cancer analysis of heterogeneity of tumor mutational burden and genomic mutation under treatment pressure

  2024cites this paper
• Tumor architecture and emergence of strong genetic alterations are bottlenecks for clonal evolution in primary prostate cancer.

  2024cites this paper
• Precision medicine for prostate cancer: An international perspective.

  2024cites this paper
• The cost-effectiveness of germline BRCA testing in metastatic prostate cancer followed by cascade testing of first-degree relatives of mutation carriers.

  2024cites this paper
• Integrative proteogenomic profiling of high-risk prostate cancer samples from Chinese patients indicates metabolic vulnerabilities and diagnostic biomarkers

  2024cites this paper
• Genomic landscape of early-stage prostate adenocarcinoma in Mexican patients: an exploratory study

  2024cites this paper
• Prostate cancer detection through unbiased capture of methylated cell-free DNA

  2024cites this paper
• Molecular Pathology of Prostate Cancer.

  2024cites this paper
• Analysis and functional validations of multiple cell death patterns for prognosis in prostate cancer.

  2024cites this paper
• CRISPR/Cas9 model of prostate cancer identifies Kmt2c deficiency as a metastatic driver by Odam/Cabs1 gene cluster expression

  2024cites this paper
• Probabilistic graph-based model uncovers previously unseen druggable vulnerabilities in major solid cancers

  2024cites this paper
• Tumor evolution metrics predict recurrence beyond 10 years in locally advanced prostate cancer

  2024cites this paper
• The Virtual Child.

  2024cites this paper
• Colibactin Exerts Androgen-dependent and -independent Effects on Prostate Cancer.

  2024cites this paper
• Nurturing the marriages of urinary liquid biopsies and nano‐diagnostics for precision urinalysis of prostate cancer

  2023cites this paper
• Our Current Understanding of the Heterogeneity in Prostate Cancer and Renal Cell Carcinoma

  2023cites this paper
• Novel signatures of prostate cancer progression and therapeutic resistance

  2023cites this paper
• A polygenic two-hit hypothesis for prostate cancer.

  2023cites this paper
• Nur77 Serves as a Potential Prognostic Biomarker That Correlates with Immune Infiltration and May Act as a Good Target for Prostate adenocarcinoma

  2023cites this paper
• Exploiting the DNA Damage Response for Prostate Cancer Therapy

  2023cites this paper
• Cancer origin tracing and timing in two high-risk prostate cancers using multisample whole genome analysis: prospects for personalized medicine

  2023cites this paper
• Heterogeneity and genomic evolution of metastatic prostate cancer

  2023cites this paper
• Loss of PDE4D7 expression promotes androgen independence, neuroendocrine differentiation and alterations in DNA repair: implications for therapeutic strategies

  2023cites this paper
• Analysis of evolutionary dynamics and clonal architecture in prostate cancer

  2023cites this paper
• Reduced PDE4D7 in prostate cancer correlates with genomic downregulation within the upstream PDE4D coding region

  2023cites this paper
• Noncoding RNA mutations in cancer

  2023cites this paper
• New insights into the biology and development of lung cancer in never smokers—implications for early detection and treatment

  2023cites this paper
• Intra-prostatic tumour evolution, steps in metastatic spread and histogenomic associations revealed by integration of multi-region whole-genome sequencing with histopathological features

  2023cites this paper
• The Adaptability of Chromosomal Instability in Cancer Therapy and Resistance

  2022cites this paper
• The BRCAness Landscape of Cancer

  2022cites this paper
• Clinical and genomic characterization of mutational signatures across human cancers

  2022cites this paper
• GENOMIC CHARACTERIZATION OF PROSTATIC BASAL CELL CARCINOMA.

  2022cites this paper
• Germline determinants of the prostate tumor genome

  2022cites this paper
• The Long and the Short of It: NEAT1 and Cancer Cell Metabolism

  2022cites this paper
• Genetic Testing and Its Clinical Application in Prostate Cancer Management: Consensus Statements from the Hong Kong Urological Association and Hong Kong Society of Uro-Oncology

  2022cites this paper
• Clonal hematopoiesis and risk of prostate cancer in large samples of European ancestry men.

  2022cites this paper
• Whole-exome sequencing of Indian prostate cancer reveals a novel therapeutic target: POLQ

  2022cites this paper
• Starfish infers signatures of complex genomic rearrangements across human cancers

  2022cites this paper
• Somatic mutations reveal complex metastatic seeding from multifocal primary prostate cancer

  2022cites this paper
• Genome-wide interrogation of structural variation reveals novel African-specific prostate cancer oncogenic drivers

  2022cites this paper
• Molecular Mechanisms Underlying the Development of Neuroendocrine Prostate Cancer.

  2022cites this paper
• The architecture of clonal expansions in morphologically normal tissue from cancerous and non-cancerous prostates

  2022cites this paper
• Nonmalignant AR-positive prostate epithelial cells and cancer cells respond differently to androgen

  2022cites this paper
• From Omics to Multi-Omics Approaches for In-Depth Analysis of the Molecular Mechanisms of Prostate Cancer

  2022cites this paper
• Non-Invasive Profiling of Advanced Prostate Cancer via Multi-Parametric Liquid Biopsy and Radiomic Analysis

  2022cites this paper
• PanCancer analysis of somatic mutations in repetitive regions reveals recurrent mutations in snRNA U2

  2022cites this paper
• Quality and Quantity: Evaluating Tumor Biology Alongside Novel Imaging on Diagnosis of Metastatic Hormone-sensitive Prostate Cancer.

  2022cites this paper
• Implementation of a prostate cancer‐specific targeted sequencing panel for credentialing of patient‐derived cell lines and genomic characterization of patient samples

  2022cites this paper
• PARP Inhibitors as Monotherapy in Daily Practice for Advanced Prostate Cancers

  2022cites this paper
• Clinical Reliability of Genomic Data Obtained from Spinal Metastatic Tumor Samples.

  2022cites this paper
• A m6Avalue predictive of prostate cancer stemness, tumor immune landscape and immunotherapy response

  2022cites this paper
• Patterns of structural variation define prostate cancer across disease states

  2022cites this paper
• [DNA repair gene alterations testing in prostate cancer : A practical update by the prostate cancer committee of the french association of urology].

  2022cites this paper
• African-specific molecular taxonomy of prostate cancer

  2022cites this paper
• Comparative genomics of primary prostate cancer and paired metastases: insights from 12 molecular case studies

  2022cites this paper
• Polygenic and Network-based studies in risk identification and demystification of cancer

  2022cites this paper
• SWAN pathway-network identification of common aneuploidy-based oncogenic drivers

  2022cites this paper
• Prostate zones and cancer: lost in transition?

  2021cites this paper
• Expression and functions of long non-coding RNA NEAT1 and isoforms in breast cancer

  2021cites this paper
• SPOP and CHD1 alterations in prostate cancer: Relationship with PTEN loss, tumor grade, perineural infiltration, and PSA recurrence

  2021cites this paper
• Evaluation of NOTCH family genes’ expression and prognostic value in prostate cancer

  2021cites this paper
• Magnetic Resonance Imaging Based Radiomic Models of Prostate Cancer: A Narrative Review

  2021cites this paper
• Cis-regulatory Element Hijacking Overshadows Topological Changes in Prostate Cancer

  2021cites this paper
• Metastatic Castration-Resistant Prostate Cancer Remains Dependent on Oncogenic Drivers Found in Primary Tumors

  2021influential citation
• Network Analysis Integrating microRNA Expression Profiling with MRI Biomarkers and Clinical Data for Prostate Cancer Early Detection: A Proof of Concept Study

  2021cites this paper
• Molecular Pathology of Prostate Cancer.

  2021cites this paper
• Testicular and prostate cancers

  2021cites this paper
• Transcriptional pro fi ling of primary prostate tumor in metastatic hormone-sensitive prostate cancer and association with clinical outcomes: correlative analysis of the E3805 CHAARTED trial 5

  2021cites this paper
• Drug Intensification in Future Postoperative Radiotherapy Practice in Biochemically-Relapsing Prostate Cancer Patients

  2021cites this paper
• Harbingers of Aggressive Prostate Cancer: Precision Oncology Case Studies

  2021cites this paper
• Non-coding driver mutations in human cancer

  2021cites this paper
• African-specific prostate cancer molecular taxonomy

  2021cites this paper
• Aging of the progenitor cells that initiate prostate cancer.

  2021cites this paper
• Transcriptional profiling of primary prostate tumor in metastatic hormone-sensitive prostate cancer and association with clinical outcomes: correlative analysis of the E3805 CHAARTED study.

  2021cites this paper
• Tumour mutations in long noncoding RNAs enhance cell fitness

  2021cites this paper
• Diagnostic Performance of Ex Vivo Fluorescence Confocal Microscopy in the Assessment of Diagnostic Biopsies of the Prostate

  2021cites this paper
• Transperineal Parallel Biopsy of the Prostate: A New Approach of Tissue Sampling for Precision Medicine

  2021cites this paper
• SWAN Identification of Common Aneuploidy-Based Oncogenic Drivers

  2021cites this paper
• Integrated Network-Based Computational Analysis for Drug Development

  2021cites this paper
• Drug-induced epigenomic plasticity reprograms circadian rhythm regulation to drive prostate cancer towards androgen-independence

  2021cites this paper
• Multiplexed functional genomic analysis of 5’ untranslated region mutations across the spectrum of prostate cancer

  2021cites this paper
• Generating human prostate cancer organoids from leukapheresis enriched circulating tumour cells.

  2021cites this paper
• Emerging biomarker associated with prognosis of prostate cancer identified via co-expression analysis

  2021cites this paper
• Experimental challenges to modeling prostate cancer heterogeneity.

  2021cites this paper
• Understanding and targeting prostate cancer cell heterogeneity and plasticity

  2021cites this paper